Cancer patients at Coventry NHS trust harmed by years of unnecessary chemotherapy, report finds

Cancer patients at an NHS trust in the United Kingdom were severely harmed after being given years of unnecessary chemotherapy, a report has found. According to the Royal College of Physicians (RCP) report, some people were misdiagnosed and given inappropriate courses of treatment, while others were incorrectly told that if they stopped chemotherapy they would die.
The report concerns the treatment of brain tumour patients at University Hospitals Coventry and Warwickshire NHS trust. It was commissioned after concerns were raised by colleagues of Prof Ian Brown, a clinical oncologist, whose patients were handed over after his retirement in 2023.
The report found his patients were on long-term repeated cycles of the chemotherapy drug temozolomide (TMZ), far longer than the usual course of treatment, without evidence that continuing it would benefit them. Some patients had been left on treatment despite their cancer progressing, when moving to supportive care for their symptoms would have been a better choice.
The report examined the cases of 20 patients. Fifteen of these were found to have received unsatisfactory care and five cases were graded as requiring improvement.
One patient had more than 10 years of chemotherapy and was told they had deadly glioblastoma. This was later found to be a grade-1 pilocytic astrocytoma, a low-grade tumour with potentially normal life expectancy that does not require chemotherapy.
Another patient had chemotherapy treatment for a decade and experienced significant toxicity, including fatigue, nausea, severe shingles requiring hospital admission, and nausea and vomiting, the report said.
Leaders at the trust have apologised for the failures. The legal firm Brabners, which is representing more than 40 patients, is calling for an independent public inquiry.
The report says the trust should ensure that all living patients treated with more than 12 cycles of TMZ have had their case independently reviewed.
Becky Jones received more than 100 cycles of chemotherapy over a 10-year period after she was incorrectly diagnosed with a grade-4 glioblastoma and told she had between six and 12 months to live. She said that for years she questioned why she was still being given chemotherapy when her scans were stable, but was repeatedly told that without it she would die. She said seeing the report independently confirm the serious failings was validating but incredibly painful, and she now needs a full and honest explanation of what happened to her.
Prof Andy Hardy, the trust's chief executive, and Sue Noyes, its chair, said they were deeply sorry to all the patients and families affected by failures within the neuro-oncology service under the care of retired clinical oncologist Ian Brown. They said an apology alone cannot undo the issues experienced, but meaningful action is being taken and they will learn from this openly, transparently and with the utmost urgency.




